292 related articles for article (PubMed ID: 2127807)
1. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Barrio JR; Huang SC; Melega WP; Yu DC; Hoffman JM; Schneider JS; Satyamurthy N; Mazziotta JC; Phelps ME
J Neurosci Res; 1990 Dec; 27(4):487-93. PubMed ID: 2127807
[TBL] [Abstract][Full Text] [Related]
2. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA.
Endres CJ; DeJesus OT; Uno H; Doudet DJ; Nickles JR; Holden JE
Front Biosci; 2004 Jan; 9():505-12. PubMed ID: 14766386
[TBL] [Abstract][Full Text] [Related]
3. 6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography.
Melega WP; Hoffman JM; Schneider JS; Phelps ME; Barrio JR
Brain Res; 1991 Mar; 543(2):271-6. PubMed ID: 1905578
[TBL] [Abstract][Full Text] [Related]
4. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
5. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.
Melega WP; Grafton ST; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
J Cereb Blood Flow Metab; 1991 Nov; 11(6):890-7. PubMed ID: 1939384
[TBL] [Abstract][Full Text] [Related]
6. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
7. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
10. The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans.
Melega WP; Hoffman JM; Luxen A; Nissenson CH; Phelps ME; Barrio JR
Life Sci; 1990; 47(2):149-57. PubMed ID: 2117691
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
Melega WP; Raleigh MJ; Stout DB; DeSalles AA; Cherry SR; Blurton-Jones M; Morton GG; Huang SC; Phelps ME
Exp Neurol; 1996 Oct; 141(2):318-29. PubMed ID: 8812167
[TBL] [Abstract][Full Text] [Related]
13. Biological imaging and the molecular basis of dopaminergic diseases.
Barrio JR; Huang SC; Phelps ME
Biochem Pharmacol; 1997 Aug; 54(3):341-8. PubMed ID: 9278092
[TBL] [Abstract][Full Text] [Related]
14. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Wahl L; Nahmias C
J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.
Huang SC; Yu DC; Barrio JR; Grafton S; Melega WP; Hoffman JM; Satyamurthy N; Mazziotta JC; Phelps ME
J Cereb Blood Flow Metab; 1991 Nov; 11(6):898-913. PubMed ID: 1939385
[TBL] [Abstract][Full Text] [Related]
16. 6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.
Doudet DJ; Wyatt RJ; Cannon-Spoor E; Suddath R; McLellan CA; Cohen RM
J Neural Transplant Plast; 1993; 4(1):27-38. PubMed ID: 7509198
[TBL] [Abstract][Full Text] [Related]
17. Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
Chiueh CC; Firnau G; Burns RS; Nahmias C; Chirakal R; Kopin IJ; Garnett ES
Adv Neurol; 1987; 45():167-9. PubMed ID: 3103385
[No Abstract] [Full Text] [Related]
18. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Yee RE; Irwin I; Milonas C; Stout DB; Huang SC; Shoghi-Jadid K; Satyamurthy N; Delanney LE; Togasaki DM; Farahani KF; Delfani K; Janson AM; Phelps ME; Langston JW; Barrio JR
Mov Disord; 2001 Sep; 16(5):838-48. PubMed ID: 11746613
[TBL] [Abstract][Full Text] [Related]
19. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
20. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
